Filings Don’t Lie: Learn Why D. E. Shaw & Co Just Purchased Exact Sciences Corp Stake?

Filings Don't Lie: Learn Why D. E. Shaw & Co Just Purchased Exact Sciences Corp Stake?

The New D. E. Shaw & Co Holding in Exact Sciences Corp

D. E. Shaw & Co filed with the SEC SC 13G form for Exact Sciences Corp. The form can be accessed here: 000114420416134165. As reported in D. E. Shaw & Co’s form, the filler as of late owns 5% or 5,450,856 shares of the Health Care–company.

Exact Sciences Corp stake is a new one for the and it was filed because of activity on November 1, 2016. We feel this shows D. E. Shaw & Co’s positive view for the stock.

Exact Sciences Corp Institutional Sentiment

Latest Security and Exchange filings show 182 investors own Exact Sciences Corp. The institutional ownership in Q3 2015 is high, at 86.44% of the outstanding shares. This is increased by 7451954 the total institutional shares. 93706565 were the shares owned by these institutional investors. In total 22 funds opened new Exact Sciences Corp stakes, 83 increased stakes. There were 33 that closed positions and 52 reduced them.

Harvey Capital Management Inc is an institutional investor bullish on Exact Sciences Corp, owning 366250 shares as of Q3 2015 for 2.63% of its portfolio. J&P China Capital Management Company owns 1844727 shares or 6.90% of its portfolio. CA Primecap Management Company have 0.05% of their stock portfolio for 2736300 shares. Further, Signalpoint Asset Management Llc reported stake worth 0.14% of its US stock portfolio. The KS Mitchell Capital Management Co owns 117959 shares. Exact Sciences Corp is 0.74% of the manager’s US portfolio.

Business Profile

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. It has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test. The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers. It also focused on developing its pipeline for future products and services.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment increased to 1.42 in 2016 Q2. Its up 0.70, from 0.72 in 2016Q1. The ratio increased, as 18 funds sold all EXACT Sciences Corporation shares owned while 41 reduced positions. 30 funds bought stakes while 54 increased positions. They now own 87.89 million shares or 11.45% more from 78.86 million shares in 2016Q1.

Ubs Asset Americas last reported 0.03% of its portfolio in the stock. Wasatch Advsrs Incorporated has 3.66 million shares for 0.69% of their US portfolio. American Natl Registered Invest Advisor holds 0.1% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS) for 18,100 shares. Redmond Asset Mngmt Lc last reported 0.52% of its portfolio in the stock. Lpl Fincl Lc last reported 25,306 shares in the company. Sva Plumb Wealth Management Limited Liability has 47,893 shares for 0.09% of their US portfolio. Teachers Advisors accumulated 154,928 shares or 0% of the stock. Proshare Advsrs has invested 0% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS). Ladenburg Thalmann Svcs owns 5,586 shares or 0% of their US portfolio. Cap World Investors accumulated 0.01% or 1.75M shares. Blackrock last reported 0% of its portfolio in the stock. Teacher Retirement Of Texas holds 13,691 shares or 0% of its portfolio. Schwab Charles Management Inc holds 322,874 shares or 0% of its portfolio. Adage Prtnrs Grp Limited Liability Co last reported 0.01% of its portfolio in the stock. Polar Asset Mgmt holds 0.11% or 212,630 shares in its portfolio.

Insider Transactions: Since July 25, 2016, the stock had 2 insider purchases, and 3 insider sales for $97,947 net activity. Shares for $90,500 were bought by Sterling Lionel. The insider COWARD D SCOTT sold 1,701 shares worth $30,584. Another trade for 7,383 shares valued at $109,416 was made by LIDGARD GRAHAM PETER on Monday, July 25. $109,060 worth of EXACT Sciences Corporation (NASDAQ:EXAS) was sold by ARORA MANEESH. Another trade for 3,380 shares valued at $60,613 was bought by Zanotti Katherine S.

The stock decreased 0.45% or $0.08 during the last trading session, hitting $17.6. About 1.93 million shares traded hands. EXACT Sciences Corporation (NASDAQ:EXAS) has risen 148.31% since April 12, 2016 and is uptrending. It has outperformed by 143.33% the S&P500.

Exact Sciences Corporation is a molecular diagnostics firm focused on the early detection and prevention of some forms of cancer. The company has a market cap of $1.96 billion. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. It currently has negative earnings. It has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer.

EXACT Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Out of 13 analysts covering EXACT Sciences (NASDAQ:EXAS), 5 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 38% are positive. $34 is the highest target while $4 is the lowest. The $13.17 average target is -25.17% below today’s ($17.6) stock price. EXACT Sciences has been the topic of 27 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Lake Street maintained EXACT Sciences Corporation (NASDAQ:EXAS) on Tuesday, November 24 with “Hold” rating. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) has “Buy” rating given on Tuesday, October 6 by TH Capital. The firm has “Buy” rating by Jefferies given on Wednesday, July 27. On Monday, August 24 the stock rating was maintained by Canaccord Genuity with “Buy”. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by BTIG Research on Friday, December 18. The firm has “Buy” rating given on Tuesday, October 6 by Roth Capital. On Thursday, February 25 the stock rating was maintained by Jefferies with “Buy”. Lake Street maintained it with “Hold” rating and $15 target price in Tuesday, November 1 report. The rating was maintained by Goldman Sachs with “Neutral” on Tuesday, October 6. The company was maintained on Wednesday, October 26 by Benchmark.

More notable recent EXACT Sciences Corporation (NASDAQ:EXAS) news were published by: Fool.com which released: “1 Sentence in Exact Sciences Corporation’s Q3 Report Cost It 16% in October” on November 07, 2016, also Fool.com with their article: “Here’s Why Exact Sciences Corporation’s Stock Is Dropping Today” published on October 26, 2016, Fool.com published: “Exact Sciences Corp. Gets a Better Balance Sheet” on November 03, 2016. More interesting news about EXACT Sciences Corporation (NASDAQ:EXAS) were released by: Prnewswire.com and their article: “Exact Sciences Appoints Jeff Elliott Chief Financial Officer” published on November 08, 2016 as well as Prnewswire.com‘s news article titled: “Exact Sciences’ Cologuard Wins Prestigious Prix Galien Award for Best Medical …” with publication date: October 28, 2016.

According to Zacks Investment Research, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.”

EXAS Company Profile

Exact Sciences Corporation, incorporated on February 10, 1995, is a molecular diagnostics firm focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. The Firm has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The Company’s Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test (FIT). The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment